US FDA approves Cimduo (lamivudine and tenofovir disoproxil fumarate) Tablets for the Treatment of HIV Infection

US FDA approves Cimduo (lamivudine and tenofovir disoproxil fumarate) Tablets for the Treatment of HIV Infection

FDA Approves Cimduo (lamivudine and tenofovir disoproxil fumarate) Tablets for the Treatment of HIV Infection

Company: Mylam Pharmaceutical Inc.

Generic Name: lamivudine and tenofovir disoproxil fumarate

Dosage Form: Tablets 

Treatment for: HIV Infection

 

 

General information about Cimduo

The U.S. Food and Drug Administration (FDA) has approved Cimduo (lamivudine and tenofovir disoproxil fumarate), a combination of two nucleo(t)side reverse transcriptase inhibitors indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Cimduo is a prescription medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) in adults and children weighing at least 35 kg.

HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).

Cimduo contains the prescription medicines lamivudine and tenofovir disoproxil fumarate.

 

 

Top